Compare Stocks

→ Will this $2 AI stock double overnight? (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$0.88	$0.99	$0.65 ▼ $1.49	$360.82M	1.98	1.99 million shs	657,243 shs
EDIT Editas Medicine	$5.35 -2.0%	$7.63	$5.28 ▼ $11.91	$439.96M	2.01	1.83 million shs	1.91 million shs
SRNE Sorrento Therapeutics	$0.02	$0.02	$0.00 ▼ $0.42	$8.27M	2.25	271,917 shs	97,454 shs

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	-0.53%	-4.20%	+4.11%	-30.27%	-31.36%
EDIT Editas Medicine	-2.01%	-4.63%	-27.31%	-31.23%	-30.52%
SRNE Sorrento Therapeutics	+33.33%	-28.57%	+150.00%	-33.33%	-93.94%

Will this $2 AI stock double overnight? (Ad)

It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!

Click here to learn more >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMRN Amarin	0.2035 of 5 stars	1.9	3.0	0.0	0.0	0.0	0.0	0.6
EDIT Editas Medicine	3.5591 of 5 stars	3.3	1.0	0.0	4.6	2.5	2.5	0.0
SRNE Sorrento Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRN Amarin	1.75	Reduce	$1.08	23.30% Upside
EDIT Editas Medicine	2.56	Moderate Buy	$15.00	180.37% Upside
SRNE Sorrento Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest AMRN, SRNE, and EDIT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
2/29/2024	EDIT Editas Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $16.00
2/29/2024	EDIT Editas Medicine	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$10.00 ➝ $11.00
2/27/2024	EDIT Editas Medicine	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRN Amarin	$306.91M	1.18	N/A	N/A	$1.35 per share	0.65
EDIT Editas Medicine	$78.12M	5.63	N/A	N/A	$4.27 per share	1.25
SRNE Sorrento Therapeutics	$62.84M	0.18	N/A	N/A	($0.05) per share	-0.40

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRN Amarin	-$59.11M	-$0.14	N/A	N/A	N/A	-19.26%	-10.47%	-6.97%	5/1/2024 (Confirmed)
EDIT Editas Medicine	-$153.22M	-$2.05	N/A	N/A	N/A	-196.12%	-42.95%	-30.49%	5/3/2024 (Estimated)
SRNE Sorrento Therapeutics	-$572.84M	N/A	0.00	∞	N/A	N/A	N/A	N/A	5/13/2024 (Estimated)

Latest AMRN, SRNE, and EDIT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2024	N/A	AMRN Amarin	-$0.0350	N/A	+$0.0350	N/A	N/A	N/A
2/29/2024	Q4 2023	AMRN Amarin	-$0.05	-$0.01	+$0.04	-$0.01	$72.46 million	$74.71 million
2/28/2024	Q4 2023	EDIT Editas Medicine	-$0.52	-$0.23	+$0.29	-$0.23	$4.84 million	$60.00 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRN Amarin	N/A	2.80	1.80
EDIT Editas Medicine	N/A	5.39	5.39
SRNE Sorrento Therapeutics	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
AMRN Amarin	22.25%
EDIT Editas Medicine	71.90%
SRNE Sorrento Therapeutics	0.02%

Insider Ownership

Company	Insider Ownership
AMRN Amarin	1.96%
EDIT Editas Medicine	1.90%
SRNE Sorrento Therapeutics	2.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRN Amarin	275	410.67 million	402.62 million	Optionable
EDIT Editas Medicine	265	82.24 million	80.67 million	Optionable
SRNE Sorrento Therapeutics	799	551.28 million	536.95 million	Optionable

AMRN, SRNE, and EDIT Headlines

Source	Headline
	Sorrento Therapeutics (NASDAQ:SRNE) Now Covered by StockNews.com americanbankingnews.com - April 21 at 2:14 AM
	Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks news.bloomberglaw.com - March 27 at 4:18 AM
	Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks news.bloomberglaw.com - March 27 at 4:18 AM
	Sorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1) news.bloomberglaw.com - March 12 at 6:20 PM
	Judge Declines to Dismiss Sorrento Therapeutics Bankruptcy Case wsj.com - March 12 at 6:20 PM
	Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc. tmcnet.com - February 27 at 9:57 AM
	Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc. businesswire.com - February 27 at 7:30 AM
	Sorrento Therapeutics pharmaphorum.com - February 7 at 10:34 AM
	5 Sanders Cove, Sorrento WA 6020 domain.com.au - January 18 at 9:02 AM
	Sorrento Therapeutics, Inc. (0L85.L) finance.yahoo.com - January 9 at 10:46 AM
	Sorrento WA 6020 domain.com.au - December 29 at 3:42 PM
	Sorrento Therapeutics Inc SRNEQ morningstar.com - November 5 at 10:27 AM
	29 Normanby Road Sorrento VIC 3943 domain.com.au - October 15 at 5:35 PM
	Sorrento, Italy - Weather Forecasts \| Maps \| News - Yahoo Weather yahoo.com - October 14 at 3:34 PM
	151 Seacrest Drive Sorrento WA 6020 domain.com.au - October 10 at 9:09 PM
	Sorrento holiday apartment accommodation with beach/lake nearby, internet access, balcony/terrace and air con holidaylettings.co.uk - October 9 at 7:15 PM
	9 Sunset Strip Sorrento VIC 3943 domain.com.au - September 14 at 9:37 AM
	Court rules Virpax CEO Anthony Mack breached his agreement with Sorrento Therapeutics bizjournals.com - September 7 at 5:29 PM
	122 Campbell Street Sorrento QLD 4217 domain.com.au - August 21 at 3:59 PM
	Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid finance.yahoo.com - August 8 at 11:08 AM
	Cheap Flights from Glasgow to Sorrento skyscanner.net - August 3 at 1:31 PM
	Cheap Flights from Edinburgh to Sorrento skyscanner.net - July 29 at 11:29 PM
	Cheap Flights from Bucharest to Sorrento skyscanner.net - July 29 at 1:28 PM
	Cheap Flights from Birmingham to Sorrento skyscanner.net - July 29 at 7:45 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Amarin

NASDAQ:AMRN

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Editas Medicine

NASDAQ:EDIT

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Sorrento Therapeutics

NASDAQ:SRNE

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial